UNASSIGNED: A retrospective analysis of initial MOG-ON and AQP4-ON cases during the COVID-19 peak and subsequent months. Patients were classified as possible COVID-19 related ON (PCRON) or non-COVID-19 related ON (NCRON). The study compared epidemiology, comorbidities, and clinical features between these groups.
UNASSIGNED: Patients with MOG-ON tended to develop ON symptoms closer in time to a mild COVID-19 infection compared to those with AQP4-ON (6.87 ± 6.25 weeks vs. 11.06 ± 5.84 weeks; p = 0.038), a significantly higher proportion of patients with MON-ON developing symptoms within 6 weeks after COVID-19 compared to those with AQP4-ON (15/23 [65.2%] vs. 5/17 [29.4%]; p = 0.025). Comparing MOG-ON and AQP4-ON patients, MOG-ON patients were more likely to have a recent infection before ON onset (73.1% vs. 30%; p = 0.007) and had better peak and post-treatment visual acuity (p = 0.01; p < 0.001). In contrast, AQP4-ON patients frequently showed comorbid connective tissue diseases (30.0% vs. 0%, p = 0.004) and antinuclear antibody abnormalities (40.0% vs. 7.7%, p = 0.012). Among MOG-ON patients, PCRON had increased rates of atherosclerotic vascular diseases (AVDs) (53.3% vs. 9.1%, p = 0.036), phospholipid antibody abnormalities (60.0% vs. 18.2%, p = 0.04), and bilateral visual impairment (66.7% vs. 9.1%, p = 0.005). Multivariate analysis pinpointed AVDs (OR = 15.21, p = 0.043) and bilateral involvement (OR = 25.15, p = 0.015) as independent factors related to COVID-19 associated MOG-ON, with both being good discriminators for PCRON (AUC = 0.879). No differences were found between the PCRON and NCRON groups in AQP4-ON patients.
UNASSIGNED: Mild COVID-19 is more likely associated with MOG-ON than AQP4-ON. MOG-ON that develops within 6 weeks following a COVID-19 infection may be associated with the COVID-19 infection. AVDs may have a synergistic effect on MOG-ON in patients with COVID-19, which warrants further investigation. COVID-19 related MOG-ON often affects both eyes, and acute visual function damage can be severe, but generally has a good prognosis.
■对COVID-19高峰和随后几个月的初始MOG-ON和AQP4-ON病例的回顾性分析。患者被分类为可能的COVID-19相关ON(PCRON)或非COVID-19相关ON(NCRON)。这项研究比较了流行病学,合并症,和这些群体之间的临床特征。
■与AQP4-ON患者相比,MOG-ON患者倾向于在时间上更接近于轻度COVID-19感染(6.87±6.25周vs.11.06±5.84周;p=0.038),与AQP4-ON患者相比,MON-ON患者在COVID-19后6周内出现症状的比例明显更高(15/23[65.2%]与5/17[29.4%];p=0.025)。比较MOG-ON和AQP4-ON患者,MOG-ON患者在ON发作前更有可能最近感染(73.1%vs.30%;p=0.007),并且具有更好的峰值和治疗后视力(p=0.01;p<0.001)。相比之下,AQP4-ON患者常表现为结缔组织病合并症(30.0%vs.0%,p=0.004)和抗核抗体异常(40.0%vs.7.7%,p=0.012)。在MOG-ON患者中,PCRON的动脉粥样硬化性血管疾病(AVDs)发病率增加(53.3%vs.9.1%,p=0.036),磷脂抗体异常(60.0%vs.18.2%,p=0.04),和双侧视力障碍(66.7%vs.9.1%,p=0.005)。多因素分析确定AVDs(OR=15.21,p=0.043)和双侧受累(OR=25.15,p=0.015)是与COVID-19相关MOG-ON的独立因素,两者都是PCRON的良好鉴别器(AUC=0.879)。在AQP4-ON患者中,PCRON和NCRON组之间没有发现差异。
■轻度COVID-19比AQP4-ON更可能与MOG-ON相关。COVID-19感染后6周内发生的MOG-ON可能与COVID-19感染有关。AVDs可能对COVID-19患者的MOG-ON有协同作用,值得进一步研究。与COVID-19相关的MOG-ON经常影响双眼,急性视觉功能损伤可能很严重,但总体预后良好。